Methotrexate eluting stents: To modify or cure?

Heart

Volumn 90, Issue 2, 2004, Pages 121-122

  Morton, A C ^b   Gunn, J ^a,b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; METHOTREXATE; PACLITAXEL; POLYMER; RAPAMYCIN;

BONE MARROW SUPPRESSION; BRACHYTHERAPY; CORONARY ARTERY; CORONARY STENT; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; EDITORIAL; ELUTION; HUMAN; IMPLANTATION; MUCOSA INFLAMMATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0742290232     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.019638     Document Type: Editorial

References (16)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with a stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
2. Stone G. TAXUS-IV: angiographic and IVUS results of the pivotal prospective, multicenter, randomized trial of polymer-based paclitaxel-eluting stents in patients with de novo lesions. Transcatheter Cardiovascular Therapeutics symposium. Washington DC, 15 September 2003 (oral presentation). www.tct.com/taxus.html
3. Huang Y, Salu K, Liu X, et al. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart 2004;90:195-9.
4. Cutolo M, Sulli A, Pizzorni C, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
5. Cox DA, Anderson PG, Roubin GS, et al. Effect of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries. Coronary Artery Dis 1992;3:237-48.
6. Malik N, Gunn J, Shepherd L, et al. Phosphorylcholine-coated stents in parcine coronary arteries: in vivo assessment of biocompatibility. J Invas Cardiol 2001;13:193-201.
7. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer coated stent. Circulation 2001;104:473-9.
8. Suzuki T, Kopia G, Hayashi S-I, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
9. 186Re liquid-filled balloon system: 6 month results from a clinical feasibility study. Cathet Cardiovasc Intervent 2002;55:28-36.
10. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-73.
11. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
12. Gunn J, Arnold ND, Chan KH, et al. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart 2002;14:447-51.
13. Abizaid A. Updates from the FIM experience: are the results durable? Transcatheter Cardiovascular Therapeutics symposium. Washington DC, 18 September 2003 (oral presentation).
14. Sianos G, Mollet N, Hofma S, et al. Late-late occlusion after intracoronary brachytherapy. Circulation 2003;108:e69-70.
15. Hirata S, Matsubara T, Saura R, et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32:1065-73.
16. Liang GC, Nemickas R, Madayag M. Multiple percutaneous transluminal angioplasties and low dose pulse methotrexate for Takayasu's arteritis. J Rheumatol 1989;16:1370-3.